Browsing Tag
NASDAQ
807 posts
Can Beam Global’s new patent finally solve the winter EV charging problem?
Beam Global (NASDAQ: BEEM) secures U.S. patent for cold-weather fast charging tech. Can this innovation revive its struggling stock and reshape EV adoption?
ZYN002 misses pivotal Fragile X trial — What does the setback mean for Harmony’s pipeline and stock outlook?
Harmony’s ZYN002 fails key Fragile X trial, sending HRMY stock lower. Find out why placebo effects mattered and what’s next for its pipeline.
Scilex Holding (SCLX) stock jumps after $200m Semnur Bitcoin deal
Scilex swaps $200M in Semnur stock for Bitcoin as SCLX jumps. See why this bold biotech-crypto move could change investor sentiment and treasury models.
The fibrosis frontier: Can anti-fibrotic drugs finally deliver where weight-loss therapies fall short?
Can anti-fibrotic drugs succeed where weight-loss therapies have stalled? Explore the future of MASH treatment and why fibrosis is the key clinical frontier.
Strive and Semler Scientific plan all-stock Bitcoin bet that unites 10,900 BTC under one roof
Strive (ASST) will buy Semler Scientific (SMLR) in a 210%-premium, all-stock Bitcoin-treasury merger. Find out how this deal could reshape corporate crypto today.
MBX Biosciences stock surges 160% after Canvuparatide Phase 2 success in hypoparathyroidism
MBX Biosciences (NASDAQ: MBX) jumps 160% after Canvuparatide Phase 2 success in hypoparathyroidism; see trial data, stock reaction, and Phase 3 outlook.
SpartanNash buyout: Why its $1.77bn C&S takeover ends a 25-year Nasdaq run and reshapes grocery supply
SpartanNash (NASDAQ: SPTN) goes private in a $1.77B C&S buyout. See what it means for shareholders, grocery rivals, and the sector’s future.
Why Envoy Medical is raising $2.5m at-the-market and what it means for COCH investors
Envoy Medical raises $2.5M via Nasdaq-compliant at-market offering. Learn how the move impacts COCH stock, liquidity, and investor sentiment.
Pfizer to buy Metsera in $7.3bn obesity drug deal, challenging Lilly and Novo
Pfizer’s $7.3B Metsera takeover could reshape the GLP-1 obesity drug race and challenge Eli Lilly and Novo Nordisk’s dominance in weight loss treatments.
Quantum Computing Inc. lands $500m oversubscribed private placement — Can QUBT turn cash into real quantum scale?
Quantum Computing Inc. secures $500M oversubscribed funding. Discover how QUBT plans to use its cash war chest to scale photonic quantum tech.